Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)
Status:
Recruiting
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and
inflammatory phenomena. Though various therapeutic possibilities have been tested against
coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been
established. Among candidate adjunct treatment options, propolis, produced by honey bees from
bioactive plant exudates, has shown potential against viral targets and has demonstrated
immunoregulatory properties.